Sep 30. [Epub ahead of print]
*Quantitative Analysis of Epstein-Barr Virus (EBV)-Related Gene Expression
in Patients with Chronic Active EBV Infection*
*Iwata S*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Iwata%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>
, *Wada K*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wada%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>
, *Tobita S*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tobita%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>
, *Gotoh K*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gotoh%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>
, *Ito Y*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ito%20Y%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>
, *Demachi-Okamura
A*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Demachi-Okamura%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>
, *Shimizu N*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shimizu%20N%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>
, *Nishiyama Y*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Nishiyama%20Y%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>
, *Kimura H*<http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kimura%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstract>
.
Department of Virology, Nagoya University Graduate School of Medicine;
Chronic active Epstein-Barr virus (EBV) infection is a systemic EBV-positive
lymphoproliferative disorder characterised by persistent or recurrent
infectious mononucleosis-like symptoms in patients with no known
immunodeficiency. The detailed pathogenesis of the disease is unknown, and
no standard treatment regimen has been developed.
EBV gene expression was analysed in peripheral blood samples collected from
24 patients with chronic active EBV infection. The expression levels of six
latent and two lytic EBV genes were quantified by real-time reverse
transcription (RT)-PCR. EBV-encoded small RNA (EBER) 1 and BamHI-A rightward
transcripts (BARTs) were abundantly detected in all patients, and latent
membrane protein (LMP) 2 was observed in most patients.
EBV nuclear antigen (EBNA) 1 and LMP1 were detected less frequently and were
expressed at lower levels. EBNA2 and the two lytic genes were not detected
in any of the patients. The pattern of latent gene expression was determined
to be latency type II. EBNA1 was detected more frequently and at higher
levels in the in clinically active patients.
Quantifying EBV gene expression is useful in clarifying the pathogenesis of
chronic active EBV infection and may provide information regarding a
patient's disease prognosis, as well as possible therapeutic interventions.
PMID: 19793909 [PubMed - as supplied by publisher]
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
Co-Cure Archives: http://listserv.nodak.edu/archives/co-cure.html
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
